Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROSERPINE PLUS (R-H-H) vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide: Not metabolized, excreted unchanged in urine. Reserpine: Metabolized in the liver via hydrolysis and conjugation. Hydralazine: Acetylation in the liver via N-acetyltransferase (NAT2).
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Hydroflumethiazide: 70% (albumin); reserpine: 96%; hydralazine: 87% (albumin and alpha-1 acid glycoprotein).
~20% bound to albumin; minimal binding to other plasma proteins.
Hydroflumethiazide: 3.6 L/kg; reserpine: 10-20 L/kg; hydralazine: 1.6 L/kg (central) and 2.7 L/kg (total).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: hydroflumethiazide 70-75%; reserpine 50-60%; hydralazine 30-50% (first-pass metabolism).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 1 tablet orally once daily; monitor electrolytes. No adjustment needed for Cr Cl >50 m L/min.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B: use with caution; reduce dose to 1 tablet orally once daily and monitor for encephalopathy.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended; inadequate safety data.
Start with 1 tablet orally once daily; titrate slowly. Monitor for orthostatic hypotension, electrolyte imbalances, and CNS effects. Avoid use in patients with depression.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
Reserpine: May cause mental depression, especially in patients with a history of depression. Discontinue at first signs of depression.
None
Hydrochlorothiazide: Electrolyte imbalance, hyperglycemia, hyperuricemia, lupus exacerbation. Reserpine: Mental depression, peptic ulcer, bradycardia. Hydralazine: Drug-induced lupus, tachycardia, myocardial ischemia, peripheral neuritis.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Reserpine: Hypersensitivity, history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma. Hydralazine: Hypersensitivity, mitral valve rheumatic heart disease, coronary artery disease. Hydrochlorothiazide: Anuria, hypersensitivity to sulfonamides, severe renal failure.
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) due to the potassium-sparing effect of the combination? Note: Actually HYDROSERPINE PLUS contains hydrochlorothiazide which is potassium-wasting; reserpine and hydralazine do not affect potassium significantly. Thus, potassium supplementation may be needed; monitor potassium levels. Limit sodium intake to control blood pressure. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) due to reserpine's potential to cause hypertensive crisis? Reserpine is not a MAOI, but caution with high-tyramine foods is advised.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not teratogenic in animal studies. Second and third trimesters: Hydrochlorothiazide may cause fetal electrolyte disturbances and thrombocytopenia; reserpine may cause neonatal bradycardia and hypotension; hydralazine may cause fetal hypotension and reflex tachycardia.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Hydrochlorothiazide is excreted in breast milk in low concentrations (M/P ratio 0.6); reserpine is excreted (M/P ratio unknown, but may cause galactorrhea and infant sedation); hydralazine is excreted in low amounts (M/P ratio not well defined). Theoretical risk of hypotensive effects in infants. Caution recommended.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No specific dose adjustments have been established for the combination; however, increased plasma volume and renal clearance in pregnancy may reduce efficacy, potentially requiring dose increase or alternative therapy. Individualize based on blood pressure response and avoid volume depletion.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Hydralazine and hydrochlorothiazide can cause lupus-like syndrome; monitor for arthralgias, rash, and fever. Reserpine depletes catecholamines, leading to potential sedation and depression; use with caution in patients with history of mood disorders. Check serum potassium and uric acid levels due to thiazide component.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying down to prevent dizziness.,Avoid driving or operating machinery until you know how this drug affects you.,Report any unusual weight gain, swelling, or shortness of breath.,Contact your doctor if you experience joint pain, fever, or rash.,Do not stop taking this medicine abruptly; it may cause blood pressure to rise.,Limit alcohol consumption as it can increase dizziness and drowsiness.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROSERPINE PLUS (R-H-H) vs ALDORIL D50, answered by our medical review team.
HYDROSERPINE PLUS (R-H-H) is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROSERPINE PLUS (R-H-H) and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROSERPINE PLUS (R-H-H) is: 1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROSERPINE PLUS (R-H-H) and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROSERPINE PLUS (R-H-H) is classified as Category C. First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not terat. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.